JP2009536956A5 - - Google Patents

Download PDF

Info

Publication number
JP2009536956A5
JP2009536956A5 JP2009510180A JP2009510180A JP2009536956A5 JP 2009536956 A5 JP2009536956 A5 JP 2009536956A5 JP 2009510180 A JP2009510180 A JP 2009510180A JP 2009510180 A JP2009510180 A JP 2009510180A JP 2009536956 A5 JP2009536956 A5 JP 2009536956A5
Authority
JP
Japan
Prior art keywords
docetaxel
use according
dose
infusion time
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009510180A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009536956A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/068727 external-priority patent/WO2007134203A2/en
Publication of JP2009536956A publication Critical patent/JP2009536956A/ja
Publication of JP2009536956A5 publication Critical patent/JP2009536956A5/ja
Pending legal-status Critical Current

Links

JP2009510180A 2006-05-12 2007-05-11 抗癌治療法 Pending JP2009536956A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80051006P 2006-05-12 2006-05-12
PCT/US2007/068727 WO2007134203A2 (en) 2006-05-12 2007-05-11 Anticancer treatments with a combination of docetaxel and ecteinascidin

Publications (2)

Publication Number Publication Date
JP2009536956A JP2009536956A (ja) 2009-10-22
JP2009536956A5 true JP2009536956A5 (enExample) 2010-05-27

Family

ID=38596836

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009510180A Pending JP2009536956A (ja) 2006-05-12 2007-05-11 抗癌治療法

Country Status (7)

Country Link
US (1) US20100009906A1 (enExample)
EP (1) EP2023931A2 (enExample)
JP (1) JP2009536956A (enExample)
AU (1) AU2007249281A1 (enExample)
CA (1) CA2652035A1 (enExample)
MX (1) MX2008014404A (enExample)
WO (1) WO2007134203A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164077A (en) * 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
SK287901B6 (sk) * 2000-11-06 2012-03-02 Pharma Mar, S. A. Use of Ecteinascidin 743 for preparation of medicament for effective antitumor treatment
GB0117402D0 (en) * 2001-07-17 2001-09-05 Pharma Mar Sa New antitumoral derivatives of et-743
CA2545054A1 (en) * 2003-11-14 2005-06-02 Pharma Mar, S.A. Combination therapy comprising the use of et-743 and paclitaxel for treating cancer
KR101287918B1 (ko) * 2004-10-26 2013-07-19 오르토 바이오테크 프로덕츠 엘.피. 엑티나시딘 743과 조합된 페길화된 리포좀 독소루비신
NZ554761A (en) 2004-10-29 2010-01-29 Pharma Mar Sa Formulations comprising ecteinascidin and a disaccharide
GB0522082D0 (en) * 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
EP2201141A1 (en) * 2007-10-19 2010-06-30 Pharma Mar S.A. Prognostic molecular markers for et-743 treatment
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164077A (en) * 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
US20040048860A1 (en) * 2000-10-31 2004-03-11 Jes Olesen Use of selective noradrenaline reuptake inhibitors for the treatment of tension-type headache
JP2005509650A (ja) * 2001-10-19 2005-04-14 ファルマ・マール・ソシエダード・アノニマ 癌治療における抗腫瘍化合物の改良した使用

Similar Documents

Publication Publication Date Title
JP2009536956A5 (enExample)
Rejhová et al. Natural compounds and combination therapy in colorectal cancer treatment
JP2016528162A5 (enExample)
ES2622559T3 (es) Combinación terapéutica que comprende un inhibidor de cdk y un agente antineoplásico
JP2009539769A5 (enExample)
JP2014512356A5 (enExample)
RU2010133489A (ru) Применение ингибиторов гамма-секретазы для лечения рака
RU2016102158A (ru) Применение эрибулина и ленватиниба в качестве комбинированной терапии для лечения рака
WO2004043389B1 (en) Methods of treating cancer and related methods
JP2016536352A5 (enExample)
JP2020523359A5 (enExample)
RU2009127351A (ru) Комбинации антифолатного агента в лечении рака
JP2020523356A5 (enExample)
RU2005141408A (ru) Комбинированное применение эктеинасцидина-743 и содержащих платину противоопухолевых соединений
JP2012522837A5 (enExample)
JP2002544231A5 (enExample)
CN103372210A (zh) 小檗碱联合化疗药物在抗肿瘤治疗中的应用
JP2014512355A5 (enExample)
JP2019511529A5 (enExample)
JP2019524713A5 (enExample)
JP2008517991A5 (enExample)
RU2007119545A (ru) Пегилированный липосомальный доксорубицин в комбинации с эктеинасцидином 743 (ecteinescidin 743)
WO2005049030A1 (en) Combination therapy comprising the use of et-743 and paclitaxel for treating cancer
RU2012108144A (ru) Противораковая терапия, направленная против раковых стволовых клеток и форм рака, устойчивых к лечению лекарственными препаратами
RU2018119085A (ru) Схема введения ингибитора фосфатидилинозитол-3-киназы